Dew, You're trying to back me in a corner here. I dont see this as a for every action there's an equal and opposite reaction sort of thing. If I were genr I'd be happy to see macugen approved. At worst genr is hoping equivalence with better administration. Why not enter a potentially bigger market? And I'd be fairly neutral if they were denied depending on the reasons. If side effects from needles in the eye were the reason for denial, genr's price tag could theoretically go way up. If systemic issues from circulating vegf were a denial reason, then that's certainly a safety issue that would apply to genr.
All in all I think this is largely a nonevent for genr stock, down 4 cents on modest volume.
Market Data 
Markets 
AI
